Effect of pantothenic acid on hippurate formation in sodium benzoate-treated HepG2 cells.

Abstract

Inborn errors of urea synthesis result in hyperammonemia. Sodium benzoate (SB) therapy has been beneficial in the treatment of hyperammonemia. It conjugates with glycine to form hippurate, which is then excreted. SB has also been used to treat children with nonketotic hyperglycinemia (NKH), where glycine is removed, on conjugation, as hippurate. In mammalian liver mitochondria, SB is activated by an ATP-dependent reaction to its CoA ester, before conjugation with glycine. Pantothenic acid (PA) is the precursor of CoA. In this investigation, increasing the amounts of PA increased CoA levels in HepG2 cells. It also significantly increased formation of hippurate in SB-treated cells. These findings suggest a beneficial effect of PA on the SB therapy in children with NKH as well as hyperammonemia.

• Authors: A Palekar
• Journal: Pediatric research (Pediatr Res) Vol. 48 Issue 3 Pg. 357-9 (Sep 2000) ISSN: 0031-3998 [Print] United States
• PMID: 10960503 (Publication Type: Journal Article)

Chemical References

• Hippurates
• Pantothenic Acid
• Sodium Benzoate
• hippuric acid

Topics

• Cell Line
• Hippurates (metabolism)
• Humans
• Metabolism, Inborn Errors (metabolism)
• Pantothenic Acid (metabolism, pharmacology)
• Sodium Benzoate (pharmacology)